236 related articles for article (PubMed ID: 36933171)
1. Advances in Targeted Therapy for Neurofibromatosis Type 2 (NF2)-Associated Vestibular Schwannomas.
Cumpston EC; Rhodes SD; Yates CW
Curr Oncol Rep; 2023 May; 25(5):531-537. PubMed ID: 36933171
[TBL] [Abstract][Full Text] [Related]
2. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
[TBL] [Abstract][Full Text] [Related]
3. Development of drug treatments for neurofibromatosis type 2-associated vestibular schwannoma.
Blakeley J
Curr Opin Otolaryngol Head Neck Surg; 2012 Oct; 20(5):372-9. PubMed ID: 22931905
[TBL] [Abstract][Full Text] [Related]
4. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
[TBL] [Abstract][Full Text] [Related]
5. An update on the CNS manifestations of neurofibromatosis type 2.
Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
[TBL] [Abstract][Full Text] [Related]
6. Molecular biology of vestibular schwannomas.
Chang LS; Welling DB
Methods Mol Biol; 2009; 493():163-77. PubMed ID: 18839347
[TBL] [Abstract][Full Text] [Related]
7. The molecular biology and novel treatments of vestibular schwannomas.
Fong B; Barkhoudarian G; Pezeshkian P; Parsa AT; Gopen Q; Yang I
J Neurosurg; 2011 Nov; 115(5):906-14. PubMed ID: 21800959
[TBL] [Abstract][Full Text] [Related]
8. The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Lu-Emerson C; Plotkin SR
Rev Neurol Dis; 2009; 6(3):E81-6. PubMed ID: 19898272
[TBL] [Abstract][Full Text] [Related]
9. Neurofibromatosis type 2.
Slattery WH
Otolaryngol Clin North Am; 2015 Jun; 48(3):443-60. PubMed ID: 26043141
[TBL] [Abstract][Full Text] [Related]
10. Neurofibromatosis Type 2: Multiple Meningiomatosis and Vestibular Schwannomas on 68 Ga-DOTATATE PET/CT.
Filizoglu N; Ozguven S
Clin Nucl Med; 2022 Nov; 47(11):e710-e712. PubMed ID: 35961372
[TBL] [Abstract][Full Text] [Related]
11. Evidence of polyclonality in neurofibromatosis type 2-associated multilobulated vestibular schwannomas.
Dewan R; Pemov A; Kim HJ; Morgan KL; Vasquez RA; Chittiboina P; Wang X; Chandrasekharappa SC; Ray-Chaudhury A; Butman JA; Stewart DR; Asthagiri AR
Neuro Oncol; 2015 Apr; 17(4):566-73. PubMed ID: 25452392
[TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
Sun S; Liu A
J Neurosurg; 2014 Dec; 121 Suppl():143-9. PubMed ID: 25434947
[TBL] [Abstract][Full Text] [Related]
13. A murine model of neurofibromatosis type 2 that accurately phenocopies human schwannoma formation.
Gehlhausen JR; Park SJ; Hickox AE; Shew M; Staser K; Rhodes SD; Menon K; Lajiness JD; Mwanthi M; Yang X; Yuan J; Territo P; Hutchins G; Nalepa G; Yang FC; Conway SJ; Heinz MG; Stemmer-Rachamimov A; Yates CW; Wade Clapp D
Hum Mol Genet; 2015 Jan; 24(1):1-8. PubMed ID: 25113746
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activation in neurofibromatosis 2-associated and sporadic schwannomas.
Sirén V; Antinheimo JP; Jääskeläinen J; Böhling T; Carpén O; Vaheri A
Acta Neurochir (Wien); 2004 Feb; 146(2):111-8. PubMed ID: 14963743
[TBL] [Abstract][Full Text] [Related]
15. Management of multiple tumors in neurofibromatosis type 2 patients.
Aboukais R; Bonne NX; Baroncini M; Zairi F; Schapira S; Vincent C; Lejeune JP
Neurochirurgie; 2018 Nov; 64(5):364-369. PubMed ID: 26071178
[TBL] [Abstract][Full Text] [Related]
16. Neurofibromatosis type 2 in an infant with multiple plexiform schwannomas as first symptom.
Miyakawa T; Kamada N; Kobayashi T; Hirano K; Fujii K; Sasahara Y; Nagai Y; Shinkai H
J Dermatol; 2007 Jan; 34(1):60-4. PubMed ID: 17204104
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis, Management, and New Therapeutic Options in Childhood Neurofibromatosis Type 2 and Related Forms.
Ruggieri M; Praticò AD; Evans DG
Semin Pediatr Neurol; 2015 Dec; 22(4):240-58. PubMed ID: 26706012
[TBL] [Abstract][Full Text] [Related]
18. Unilateral vestibular schwannoma and meningiomas in a patient with PIK3CA-related segmental overgrowth: Co-occurrence of mosaicism for 2 rare disorders.
Mills JR; Moyer AM; Kipp BR; Poplawski AB; Messiaen LM; Babovic-Vuksanovic D
Clin Genet; 2018 Jan; 93(1):187-190. PubMed ID: 28737257
[TBL] [Abstract][Full Text] [Related]
19. Sustained response to bevacizumab in a patient with mosaic neurofibromatosis type 2 carrying the
Basenach E; Förster A; Raab P; Alzein S; Schmidt G; Krauss JK; Schlegelberger B; Heidenreich F; Auber B; Hartmann C; Wiese B; Weber RG
Clin Neuropathol; 2022; 41(4):162-167. PubMed ID: 35445657
[TBL] [Abstract][Full Text] [Related]
20. Updates on Tumor Biology in Vestibular Schwannoma.
Nourbakhsh A; Dinh CT
Otolaryngol Clin North Am; 2023 Jun; 56(3):421-434. PubMed ID: 37121611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
